NCT06855069View on ClinicalTrials.gov

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

March 7, 2025

Primary Completion Date

March 7, 2027

Study Completion Date

March 7, 2029

Conditions
Ovarian Cancer
Interventions
DRUG

HS-20089

HS-20089 dose 1

DRUG

Paclitaxel

Paclitaxel dose 2

DRUG

Doxorubicin

Doxorubicin dose 3

DRUG

Topotecan

Topotecan dose 4

Trial Locations (1)

Unknown

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Hansoh BioMedical R&D Company

INDUSTRY